ATYR — ATYR PHARMA INC
Public company
InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.
Sourced from SEC EDGAR public filings
Why are billionaires buying ATYR?
Built from public SEC filings and public economic data. Not a recommendation.
Why? — Evidence & Confidence ▾
Of 3 tracked investors who changed their ATYR position last quarter, 0 bought and 3 sold (0% buy-side). Macro conditions are a headwind for this sector (Macro Tailwind 38/100 in a Expansion regime).
- +2 tracked investors reported holding ATYR at their latest filing
- −3 tracked investors reduced or exited last quarter (2 reduced, 1 sold out)
- −Current Expansion regime has historically been a headwind for this sector (Macro Tailwind 38/100)
- −13F data is disclosed up to 45 days after quarter end — positions may have changed since
- · 13F disclosure lag (up to 45 days)
- · Tracked investors are a sample, not the whole market
- · Sector regime fit is a historical average, not a guarantee
Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 11/22/2026.
About ATYR PHARMA INC (ATYR)
ATYR PHARMA INC (ATYR) appears in the most recent 13F filings of 2 tracked institutional investors. The largest disclosed position is held by Steve Cohen (Point72 Asset Management), valued at $18M. Across recent filings, tracked investors recorded 6 new positions, 7 increased, 6 reduced, and 4 exited. All data sourced from SEC 13F filings.
Based on recent institutional activity in ATYR
How many top investors track ATYR
Only 2 tracked investors report this position.
ATYR Ownership Composition
How ATYR PHARMA INC is held across tracked investor types, based on reported 13F positions.
- Multi-Strategy / Quant100.0%
Tracked investors currently reporting ATYR
2 tracked investors have since exited this position — listed separately below.
- Izzy EnglanderSep 30, 2026Millennium ManagementShares581.3KValue$176.1K% Portfolio0.00%
- Ken GriffinSep 30, 2026Citadel AdvisorsShares309.7KValue$93.8K% Portfolio0.00%
Previously held ATYR
These investors reported ATYR in an earlier quarter but not in their most recent 13F. Figures below are their last reported position, not a current holding.
| Investor | Firm | Last reported shares | Value then | Last held |
|---|---|---|---|---|
| Steve Cohen | Point72 Asset Management | 37.3K | $22.2K | Jun 30, 2026 |
| Paul Tudor Jones | Tudor Investment Corp | 500K | $360.7K | Sep 30, 2025 |
Recent activity
- Reduced$176.1K(-11.40%)Nov 16, 2026
- Sold$0(-100.00%)Nov 16, 2026
- Reduced$93.8K(-80.00%)Nov 16, 2026
- Increased$191.2K(2.09%)Nov 14, 2024
- Increased$1.3M(238.67%)Feb 14, 2025
- Increased$4.8M(334.54%)May 15, 2025
- Increased$8.4M(3.20%)Aug 14, 2025
- Sold$0(-100.00%)Feb 17, 2026
- $1.3MMay 15, 2026
- Reduced$391.5K(-60.03%)Aug 14, 2026
- Reduced$1.7M(-46.75%)Nov 14, 2024
- Increased$1.2M(602.81%)May 15, 2025
- Increased$2.3M(16.95%)Aug 14, 2025
- Sold$0(-100.00%)Nov 14, 2025
- Increased$924K(661.30%)Aug 14, 2026
- New$17.7MFeb 14, 2025
- Reduced$8.6M(-41.76%)Jul 21, 2025
- Reduced$5M(-65.24%)Aug 14, 2025
- Sold$0(-100.00%)Nov 14, 2025
- New$22.2KAug 14, 2026
- $360.7KDec 9, 2025
- New$2.9MAug 14, 2024
- $121.8KMay 15, 2024
Frequently asked questions
- How many institutional investors hold ATYR?
- 2 tracked institutional investors disclosed a position in ATYR (ATYR PHARMA INC) in their most recent 13F filing.
- Who is the largest institutional holder of ATYR?
- Steve Cohen, Point72 Asset Management, holds the largest disclosed position in ATYR, valued at $18M.
- Did institutional ownership of ATYR increase or decrease?
- Across recent 13F filings, tracked investors recorded 6 new positions, 7 increased, 6 reduced, and 4 fully exited ATYR.
- Where does this ATYR ownership data come from?
- SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.